Cereno Scientific expands its pipeline — signs agreement on acquisition of compound in pre-clinical phase
Cereno Scientific announced today that the company has signed an agreement with Emeriti Bio AB regarding the acquisition of the compound EB014. The compound has innovative properties and will expand Cereno Scientific’s portfolio in cardiovascular diseases.“After the positive results we received from the first clinical study with CS1 and an upcoming Phase II study planned, this is the right time to broaden our operations. The acquisition means we now have a portfolio of drug candidates with potential for several indications in cardiovascular diseases,” says Cereno Scientific CEO Sten R.